Literature DB >> 22896756

Introduction to monoclonal antibodies.

Jean-Pierre Mach1.   

Abstract

Keywords:  cancer immunotherapy enhancement; monoclonal anti-cancer antibodies; radiolabeled antibodies

Mesh：

Substances：

Year:  2012        PMID： 22896756      PMCID： PMC3380352     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN： 1424-9634


× No keyword cloud information.
  83 in total

Review 1.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

2.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  (124)I-huA33 antibody PET of colorectal cancer.

Authors:  Jorge A Carrasquillo; Neeta Pandit-Taskar; Joseph A O'Donoghue; John L Humm; Pat Zanzonico; Peter M Smith-Jones; Chaitanya R Divgi; Daniel A Pryma; Shutian Ruan; Nancy E Kemeny; Yuman Fong; Douglas Wong; Jaspreet S Jaggi; David A Scheinberg; Mithat Gonen; Katherine S Panageas; Gerd Ritter; Achim A Jungbluth; Lloyd J Old; Steven M Larson
Journal:  J Nucl Med       Date:  2011-07-15       Impact factor: 10.057

4.  Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).

Authors:  Michael Jäger; Alexandra Schoberth; Peter Ruf; Juergen Hess; Michael Hennig; Barbara Schmalfeldt; Pauline Wimberger; Michael Ströhlein; Bettina Theissen; Markus M Heiss; Horst Lindhofer
Journal:  Cancer Res       Date:  2011-11-01       Impact factor: 12.701

5.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; D J Bodkin; C A White; T M Liles; I Royston; C Varns; J Rosenberg; R Levy
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

7.  Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma.

Authors:  H F Sears; D Herlyn; Z Steplewski; H Koprowski
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

8.  In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.

Authors:  Alena Donda; Valérie Cesson; Jean-Pierre Mach; Giampietro Corradin; F James Primus; Bruno Robert
Journal:  Cancer Immun       Date:  2003-08-14

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen.

Authors:  S Folli; G Wagnières; A Pèlegrin; J M Calmes; D Braichotte; F Buchegger; Y Chalandon; N Hardman; C Heusser; J C Givel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205
View more
  3 in total

Review 1.  Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.

Authors:  Ylenia Ingrasciotta; Paola M Cutroneo; Ilaria Marcianò; Thijs Giezen; Fabiola Atzeni; Gianluca Trifirò
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

2.  Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.

Authors:  Simona Lucchesi; Ilaria Marcianò; Paolo Panagia; Rosanna Intelisano; Maria Pia Randazzo; Carmela Sgroi; Giuseppe Altavilla; Mariacarmela Santarpia; Vincenzo Adamo; Tindara Franchina; Francesco Ferraù; Paolina Reitano; Gianluca Trifirò
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 3.580

Review 3.  Engineering Next-Generation CAR-T Cells for Better Toxicity Management.

Authors:  Alain E Andrea; Andrada Chiron; Stéphanie Bessoles; Salima Hacein-Bey-Abina
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.